Van Lanschot Kempen Investment Management N.V. Has $22.24 Million Stake in Eli Lilly and Company (NYSE:LLY)

Van Lanschot Kempen Investment Management N.V. lifted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 33.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,804 shares of the company's stock after acquiring an additional 7,255 shares during the period. Van Lanschot Kempen Investment Management N.V.'s holdings in Eli Lilly and Company were worth $22,237,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $8,407,908,000. Proficio Capital Partners LLC lifted its stake in Eli Lilly and Company by 100,387.1% during the fourth quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after purchasing an additional 5,197,038 shares during the period. Wellington Management Group LLP boosted its holdings in Eli Lilly and Company by 19.0% during the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after purchasing an additional 2,012,129 shares in the last quarter. Capital International Investors grew its stake in shares of Eli Lilly and Company by 23.2% in the 4th quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after purchasing an additional 1,645,222 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $1,240,653,000. Institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Trading Up 0.4 %

Shares of Eli Lilly and Company stock traded up $3.03 during trading on Wednesday, hitting $830.57. 2,712,888 shares of the company were exchanged, compared to its average volume of 3,432,615. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market capitalization of $787.52 billion, a P/E ratio of 70.93, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The firm's fifty day moving average price is $827.10 and its 200 day moving average price is $818.99. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Guggenheim decreased their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research note on Tuesday. They set an "overweight" rating and a $975.00 price objective on the stock. Finally, Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a research note on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $1,017.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.